The Nature of Progression in Parkinson’s Disease: An Application of Non-Linear, Multivariate, Longitudinal Random Effects Modelling

Abstract

BackgroundTo date, statistical methods that take into account fully the non-linear, longitudinal and multivariate aspects of clinical data have not been applied to the study of progression in Parkinson’s disease (PD). In this paper, we demonstrate the usefulness of such methodology for studying the temporal and spatial aspects of the progression of PD. Extending this methodology further, we also explore the presymptomatic course of this disease.MethodsLongitudinal Positron Emission Tomography (PET) measurements were collected on 78 PD patients, from 4 subregions on each side of the brain, using 3 different radiotracers. Non-linear, multivariate, longitudinal random effects modelling was applied to analyze and interpret these data.ResultsThe data showed a non-linear decline in PET measurements, which we modelled successfully by an exponential function depending on two patient-related covariates duration since symptom onset and age at symptom onset. We found that the degree of damage was significantly greater in the posterior putamen than in the anterior putamen throughout the disease. We also found that over the course of the illness, the difference between the less affected and more affected sides of the brain decreased in the anterior putamen. Younger patients had significantly poorer measurements than older patients at the time of symptom onset suggesting more effective compensatory mechanisms delaying the onset of symptoms. Cautious extrapolation showed that disease onset had occurred some 8 to 17 years prior to symptom onset.ConclusionsOur model provides important biological insights into the pathogenesis of PD, as well as its preclinical aspects. Our methodology can be applied widely to study many other chronic progressive diseases.

Striatal dopamine in Parkinson disease: A meta‐analysis of imaging studies

“…30 Although the exponential shape of neurodegeneration may, at least partially, be artifactual and a result of lack of sensitivity at the extremes, a recent study with random effects modeling firmly supported the model. 31 An exponential decay can also be seen in animal models of PD such as the mouse 6hydroxydopamine model and in models of hereditary neurodegeneration. 32 Finally, the cardinal motor symptoms of PD also appear to behave nonlinearly, with faster progression early in the disease than in later years.…”

Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers

“…An alternative approach is to label the DAT ligand with 99m Tc, which is an isotope that is widely used in clinical nuclear medicine. Striatal DAT binding correlates with loss of nigrostriatal dopamine terminals, but may only correlate with nigral neurons when that loss does not exceed 50%, whereas direct imaging of midbrain uptake correlates with residual nigral neurons; thus, striatal DAT may not reflect disease progression beyond mild‐to‐moderate disease . Striatal or nigral uptake may therefore be a useful imaging biomarker.…”

A review of disease progression models of Parkinson's disease and applications in clinical trials

“…Modeling a biological measurement has also been done with assessments of presynaptic dopaminergic integrity using positron emission tomography (PET) measurements. 51 Supposing that these measurements are appropriate as biomarkers, the analysis done by Kuramoto et al was able to suggest that pathophysiological changes might occur up to 17 years prior to symptomatic onset in some patients. Initial regression models at least 4 years prior to Kuramoto's article lend support to the claim that the measurements could serve as a biomarker.…”